Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$1.10 USD
+0.05 (4.76%)
Updated Nov 7, 2025 10:44 AM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALLO 1.10 +0.05(4.76%)
Will ALLO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ALLO
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLO
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Halozyme (HALO) and Progyny (PGNY)
Technical picture remains unchanged for ALLO after it falls 5.41% on November 6
Allogene signals pivotal ALPHA3 interim data and ALLO-329 proof-of-concept in first half 2026 while maintaining cash runway into H2 2027
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ...